Context Therapeutics Ownership
| CNTX Stock | USD 0.83 0.00 0.000002% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 58.4 M | Current Value 95.2 M | Avarage Shares Outstanding 23.4 M | Quarterly Volatility 25.8 M |
Context Stock Ownership Analysis
About 80.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. Context Therapeutics recorded a loss per share of 0.28. The entity had not issued any dividends in recent years. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Context Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on Context Therapeutics please contact the company at 267-225-7416 or go to https://www.contexttherapeutics.com.Context Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Context Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Context Therapeutics backward and forwards among themselves. Context Therapeutics' institutional investor refers to the entity that pools money to purchase Context Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alyeska Investment Group, L.p. | 2025-03-31 | 1.7 M | Woodline Partners Lp | 2025-03-31 | 1.4 M | Sio Capital Management, Llc | 2025-03-31 | 1.3 M | Ally Bridge Group (ny) Llc | 2025-03-31 | 1.2 M | Allostery Investments Lp | 2025-03-31 | 950.2 K | Blackrock Inc | 2025-03-31 | 849 K | Affinity Asset Advisors, Llc | 2025-03-31 | 660.6 K | Geode Capital Management, Llc | 2025-03-31 | 639.2 K | Renaissance Technologies Corp | 2025-03-31 | 425.5 K | Mpm Oncology Impact Management Lp | 2025-03-31 | 14.7 M | Avidity Partners Management Lp | 2025-03-31 | 7.5 M |
Context Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Context Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Context Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Context Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Context Therapeutics Outstanding Bonds
Context Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Context Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Context bonds can be classified according to their maturity, which is the date when Context Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.